Patients & Public Our Providers Cancer & Blood Disorders About Texas Oncology Our Locations
Cancer and Blood Disorders
print

Texas Oncology Physician Publications

Date Physicians Publication Title
2008 Esler, William Vance, M.D.
Lim, S.H., Zhang, Y., Zhang, J., Periman, P.O., Burris, C., Townsend, M.
Leukemia and Lymphoma   B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period.
2008 Esler, William Vance, M.D.
Lim, S.H., Periman, P.O., Beggs, D., Zhang, Y., and Townsend, M.
British Journal of Haematology   R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
2008 Hoverman, J. Russell M.D.
Radebaugh, K.A.
American Society Clinical Oncology   Imaging in Early Breast Cancer
2008 Hutson, Thomas E. D.O., PharmD, FACP
G Sonpavde, MD Galsky.
Expert Review of Anticancer Therapy   Current optimal chemotherapy for advanced urothelial cancer.
2008 Jones, Stephen E. M.D.
Luc Yves Dirix, Jorge Ignacio, Shona Nag, Poonamally Bapsy, Henry Gomez, Digumarti Raghunadharao, Robert Paridaens, Silvia Falcon, Marina Carpentieri, Antonello Abbattista, Jean-Pierre Lobelle
Journal of Clinical Oncology   Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination with Celecoxib
2008 Lim, S.H. M.D.
Zhang, Y., Burris, C. and Townsend, M.
Bone Marrow Transplant   Successful salvage with unrelated umbilical cord blood transplant for Hodgkin’s disease relapsed following autologous stem cell transplant.
2008 McCollum, David M.D.
Richards D, Wilfong L, Sborov M, Boehm KA, Zhan F, and Asmar L.
Annals of Oncology   Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
2008 Sonpavde, Guru M.D.
Hutson TE, Rini BI
Expert Opinions on Investigational Drugs   Axitinib for renal cell carcinoma: review.
2008 Sonpavde, Guru M.D.

Thomson Scientific   Bladder cancer updates from the International Kidney and Bladder cancer Congress.
2008 Sonpavde, Guru M.D.
Hutson TE, and Berry WR.
Clinical Genitourinary Cancer   Clinical trial summary: Sunitinib malate for the therapy of hormone refractory prostate cancer progressing after prior docetaxel chemotherapy.
2008 Sonpavde, Guru M.D.
Hutson TE, Holmes FA, Richards D, von Hoff DD.
Drug Development Research   Neoadjuvant therapy as a paradigm to develop new drugs for cancer therapy.
2008 Sonpavde, Guru M.D.
Amiel GE, Mims MP, et al.
Expert Opinions in Pharmacology   Neoadjuvant therapy preceding cystectomy for locally advanced bladder cancer.
2008 Sonpavde, Guru M.D.
Hutson TE, Sternberg CN
Hot topics in Oncology   New agents in the treatment of advanced renal cancer- how does one choose among them?
2008 Sonpavde, Guru M.D.
Sternberg CN
Updates in Cancer Therapy   Novel agents for testicular germ cell tumors.
2008 Sonpavde, Guru M.D.
Fleming MT, and Sternberg CN
Updates in Cancer Therapy   Novel agents in development for prostate cancer.
2008 Sonpavde, Guru M.D.
Galsky MD, and Sternberg CN
Updates on Cancer Therapy   Novel agents in development for renal cell carcinoma.
2008 Sonpavde, Guru M.D.
Galsky MD, Hutson TE, von Hoff DD
American Journal Clinical Oncology   Patient selection for phase II clinical trials: Commentary.
2008 Sonpavde, Guru M.D.
Hutson TE, and Sternberg CN.
Expert Opinion on Investigative Drugs   Pazopanib for renal cell carcinoma.
2008 Sonpavde, Guru M.D.
Hutson TE, and Sternberg CN
European Oncology   The future of therapy for advanced renal cell cancer.
2008 Weintahl, Joel M.D.
Kishnani PS, Grabowski GA, Mistry PK, Weinreb NJ
  CME Monograph sponsored by Duke University School of Medicine: Skeletal and hematologic pathology of Type-1 Gaucher disease.
2007 Barker Jr., Jerry L., M.D.
O’Daniel JC, Rosenthal DI, Garden AS, Ahamad A, Ang KK, Asper JA, Blanco AI, de Crevoisier R, Holsinger FC, Patel CB, Schwartz DL, Wang H, Dong L.
American Journal of Clinical Oncology   The effect of dental artifacts, contrast media, and experience on interobserver contouring variations in head and neck anatomy.
2007 Blum, Joanne L. M.D., Ph. D.
Kauff ND, Domcheck SM, Freibel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch HT, Eeles RA, Neuhasusen SL, Daly MB, Matloff E, Norton L, Offit K, Rebbeck TR.
Journal of Clinical Oncology   Recall injury from vinblastine: a case report.
2007 Blum, Joanne L. M.D., Ph.D.
Freibel TM, Domcheck SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.
Clinical Breast Cancer   Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 Mutation Carriers.
2007 Blum, Joanne L. M.D., Ph.D.
Savin M, Edelman G, Pippen J, Robert N, Geister B, Kirby R, Clawson A, O’Shaughessy J.
Clinical Breast Cancer   Phase 2 study of weekly nab-Paclitaxel for the treatment of patients with metastatic breast cancer heavily pretreated with taxanes.
2007 Blum, Joanne L. M.D., Ph.D.
Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Amar L, and O’Shaughnessy JA.
Clinical Breast Cancer   Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
2007 Bordelon, James H., M.D.
Jones, S.E., et. al.
Journal of Clinical Oncology   Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
2007 Estil A. Vance III, M.D.
Drew J. Winson, Jo-Anne H. Young, Vinod Pullarkat, Genovefa A. Papanicolaou, Ravi Vij, George J. Alangaden, Roy F., Chemaly, Finn Petersen, Nelson Chao, Jared Klein, Kellie Sprague, Stephen A. Villano, and Michael Boeckh.
Blood   Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.
2007 Estil A. Vance III, M.D.
Agura E, Berryman R, Cooper B, Fay J, Holmes H, Maisel C, Molina A, Pineiro L.
  Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsede AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity.
2007 Fay, Joseph Wayne, M.D.
Palucka A, Banchereau J, Vence L, Connolly J, Uneo H.
Journal of Clinical Oncology   Compresensive analysis of melanoma antigen specific T cell repertoire. EPIMAX (Epitope MAXimum)
2007 Fay, Joseph Wayne, M.D.
Banchereau, J., Palucka, K
Journal of Clinical Oncology   Long-term survival in patients with metastatic melanoma vaccinated with melanoma-antigen loaded dendritic cells.
2007 Goldman, Stan M.D.
Rakheja D, Wilson K, Lenarsky C, Weinthal J, Schultz R.
Pediatric and Developmental Pathology   Translocation associated primitive round cell sarcoma: report of a case and review of the literature.
2007 Hellerstedt, Beth M.D.
Bosserman LD, Smith JA, Geier L. 
  Hereditary Cancer Testing in Community Oncology Practices.
2007 Hoverman, J. Russell M.D.
et. al.
Journal of Clinical Oncology   Assessment of medication safety in the outpatient setting.
2007 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde
Current Oncology Report   A novel multitargeted tyrosine kinase inhibitor.
2007 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde and BJ Roth
Oncologist   Management of recurrent testicular germ cell tumors.
2007 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde, K Chi, T Powles, CJ Sweeney, N Hahn, MD Galsky, WR Berry and D Kadman.
Cancer   Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
2007 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde, T Powles, CJ Sweeney, MD Galsky, N Hahn, and CN Sternberg. 
British Journal of Urology International   Novel agents for urothelial cancer: review
2007 Hutson, Thomas E. DO, PharmD, FACP
George, T Mekhail, L Wood, J Finke, P Elson, R Dreicer, and RM Bukowski.
Cancer Chemotherapy and Pharmacology   Phase I trial of PEG-Intron and rIL-2 in patients with metastatic renal cell carcinoma
2007 Hutson, Thomas E. DO, PharmD, FACP
E Segota, T Mekhail, T Olencki, R Dreicer, B Wacker, B Osterwalder, P Elson, M Zhou, and RM Bukowski
Urology Oncology   Phase II trial of capecitabine and rHU-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy and moderate toxicity.
2007 Hutson, Thomas E. DO, PharmD, FACP
RJ Motzer, P Tomczak, MD Michaelson, RM Bukowski, O Rixie, S Oudard, S Negrier, C Szczylik, ST Kim, I Chen, CM Baum and RA Figlin
New England Journal of Medicine   Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma.
2007 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde
Expert Opinion on Biological Therapy   Recent advances in the therapy of renal cancer.
2007 Hutson, Thomas E. DO, PharmD, FACP
RA Figlin
The Cancer Journal   Renal Cell Carcinoma: Recent Advances.
2007 Hutson, Thomas E. DO, PharmD, FACP

Expert Review of Anticavity Therapy   Safety and tolerability of sorafenib in clear-cell renal cell carcinoma – a phase III overview.
2007 Hutson, Thomas E. DO, PharmD, FACP

Baylor Health Care Center Proceedings   Targeted therapy for renal cell carcinoma: A new treatment paradigm
2007 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde and M Galsky
Clinical Genitourinary Cancer   Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma. Rationale and ongoing clinical trials.
2007 Hutson, Thomas E. DO, PharmD, FACP
RA Figlin
Oncology   The evolving role of novel targeted agents in renal cell carcinoma.
2007 Hutson, Thomas E. DO, PharmD, FACP
B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A. Desai, F. Rolland, T. Demkow, M. Gore, S Freeman, B Schwartz, M. Shan, R. Simantov, R.M. Bukowski for the Sorafenib TARGETs Clinical Trial Group.
New England Journal of Medicine   Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs)
2007 Jones, Stephen E. M.D.

Values in Health   Cost-Effectiveness of Switching to Exemestane Following Two-to-Three Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
2007 Jones, Stephen E. M.D.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jassem J, Van deVelde CJH, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich  K, Coates AS, Bajetta E, Holmberg SB, Dodwell Dl, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM
The Lancet   Survival and Saftety of Exemestane Versus Tamoxifen After 2-3 Years Tamoxifen Treatment (Intergroup Exemestane Study)
2007 Jones, Stephen E. M.D.

Community Oncology   The AC vs TC Trial: A Personal Perspective.
2007 Jones, Stephen E. M.D.
Paterson, A.
Oncology Consultations   Treatment of a Patient with Estrogen Receptor-Positive/Progesterone Receptor-Negative Early-Stage Breast Cancer with Borderline Osteopenia.
2007 Lim, S.H. M.D.
Li, Z., Li, W., Meklat, F., Wang, Z., Zhang, J., Zhang, Y.
International Journal of Cancer   A yeast two-hybrid system using Sp17 identified Ropporin as a novel Cancer-Testis antigen in hematologic malignancies.
2007 Lim, S.H. M.D.
Meklat, F., Li, Z., Wang, Z., Zhang, Y., Zhang, J., Jewell, A.
British Journal of Haematology   Cancer-Testis antigens in haematologic malignancies.
2007 Lim, S.H. M.D.
Rohrer, J.E., and Bock, A.F.
American Journal of Hospice and Palliative Medicine   Medical condition is related to treatment preference in cancer patients: Implications for quality assessment.
2007 Mearley, J. Michael M.D.
Liming, J., McGuire, F.R., Ochran, T., Kerly, J.M., and McLemore, T.L.
Journal of Bronchology   Implantation of Radiotherapy Monitoring Devices Into Peripheral Lung Cancers via Electromagnetically Guided Bronchoscopy of Highly Selective External Beam Radiation Therapy
2007 Mearley, J. Michael M.D.
McLemore, T.L., Parkhill, B., and Ochran, T.G.
New England Journal of Medicine   Recurrent Pulmonary Neurofibromatosis Type 1 Successfully Treated with Endobronchial High Dose 192 Iridium Theraphy.
2007 Mennel, Robert G. M.D., FACP
Harris L, Fritsche H, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF. Bast RC Jr.
Journal of Clinical Oncology   American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
2007 Munoz, Louis L. M.D.
Bowers, D., Gargan, L., Weprin, B., Mulne, Al, Elterman, R., Giller, C., and Winick, N.
1 Suppl. Pediatrics   Impact of Site of Tumor Reccurence Upon Survival of Children With Recurrent or Progressive Medulloblastoma .
2007 Patt, Debra M.D.
Duan, Zhigang. Fang, Shenying. Hortobagyi, Gabriel N. and Giordano, Sharon H.
Journal of Clinical Oncology   Acute Myeloid Leukemia after Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk.
2007 Pippen, John E., JR. MD, F.A.C.P.
Jones SE, Cantrell J, Vukelja S, et al.
Journal of Clinical Oncology   Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: a report of a tamoxifen exemestane adjuvant multicenter trial substudy.
2007 Pippen, John E., JR. MD, F.A.C.P.
Gong Y, Yan K, et al.
The Lancet   Determination of oestrogen-receptor status and erb b2 status of breast carcinoma: a gene expression profiling study.
2007 Pippen, John E., JR. MD, F.A.C.P.

Journal of Oncology Practice   Maintenance of certification: my perspective.
2007 Pippen, John E., JR. MD, F.A.C.P.
Blum J, Savin M, Edelamn G, et al.
Clinical Breast Cancer   Phase II study of weekly albumin bound paclitaxel for patients with breast cancer heavily pretreated with taxanes.
2007 Shivnani, Anand M.D.

Journal of the American Medical Association   Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer (Letter ot Editor)
2007 Shivnani, Anand M.D.
 Small W Jr., Stryker SJ, et al.
American Journal of Surgery   Preoperative chemoradiation in rectal cancer: results of multimodality management and analysis of prognostic factors.
2007 Shivnani, Anand M.D.

New England Journal of Medicine   Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer.
2007 Sonpavde, Guru M.D.
Hutson TE
CMP Healthcare   Advanced Clear Cell Carcinoma: Immunologic Characteristics and Results with Vaccines and Cytokines In New Treatment Paradigms in Renal Cell Cancer.
2007 Sonpavde, Guru M.D.
Galsky MD, Hutson TE
Summer 2007 Touch Briefings.   Chemotherapy for urothelial cancer.
2007 Sonpavde, Guru M.D.
Aparicio A, Guttierez I, et al.
Clinical Genitourinary Cancer   Clinical trial summary: Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.
2007 Sonpavde, Guru M.D.
Lerner SP
Oncology   Neoadjuvant therapy for bladder cancer.
2007 Sonpavde, Guru M.D.
Chi KN, Powles T, et al.
Cancer   Neoadjuvant therapy for clinically localized prostate cancer.
2007 Sonpavde, Guru M.D.
Ross R, Powles T, Sweeney CJ, Hahn N, Galsky MD, Hutson TE, Lerner SP, Sternberg CN.
British Journal of Urology International   Novel agents for muscle-invasive and advanced urothelial cancer.
2007 Sonpavde, Guru M.D.
Hutson TE
Current Oncology Reports   Novel Multi-targeted Tyrosine Kinase Inhibitor.
2007 Sonpavde, Guru M.D.
Hutson TE
Summer 2007 ASCO News and Forum   PSA screening: Pro.
2007 Sonpavde, Guru M.D.
Hutson TE
Expert Opinion on Biological Therapy   Recent advances in the therapy of renal cancer.
2007 Sonpavde, Guru M.D.
Hutson TE and Roth BJ.
Oncologist   Salvage chemotherapy for testicular germ cell tumors.
2007 Sonpavde, Guru M.D.
Hutson TE and Berry WR
Clinical Genitourinary Cancer   Systemic chemotherapy for urothelial cancer.
2007 Sonpavde, Guru M.D.
Hutson TE, and Galsky
Clinical Genitourinary Cancer   Targeting growth factor and anti-angiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
2007 Sonpavde, Guru M.D.
Spencer DM, Slawin KM
Urology Oncology   Vaccine therapy for prostate cancer.
2006 Balasubramanian, Lakshmi M.D.
Bennett CL, Evens AM, Andritsos LA, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS.
British Journal of Haematology   Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
2006 Balasubramanian, Lakshmi M.D.
Evens, AM.
Current Opinions in Oncology   Targeting angiogenesis for the treatment of sarcoma.
2006 Barker Jr., Jerry L., M.D.
Rosenthal DI, Asper JA, Garden AS, Chao KSC, Morrison WH, Weber RS, Ang KK.
Head Neck   Importance of patient examination to clinical quality assurance in head and neck radiation.
2006 Berges, Daniel Farray, M.D.
Clark, J.I.
Clinical and Applied Immunology Reviews   Vaccine therapy of malignant melanoma.
2006 Blum, Joanne L. M.D., Ph.D.
O’Shaughnessy, JA.
Clinical Breast Cancer   Capecitabine/taxane combination therapy: evolving clinical utility in breast cancer.
2006 Blum, Joanne L. M.D., Ph.D.
Dees EC, Chacko A, Loane L, Ethirajan S, Hopkins J, McMahon R, Merten S,  Negron A, Neubauer M, Ilegbodu D, Boehm K, Asmar L, O’Shaughnessy JA.
Journal of Clinical Oncology   Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
2006 Blum, Joanne L. M.D., Ph.D.
Jones SE, Savin MA. Holmes FA, O’Shaughnessy JA, Vukelja S, McIntryre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Mayer WG, and Asmar L,.
Journal of Clinical Oncology   Results of a Phase III trial doxoroubicin/cyclophosphamide (AC) compared to docetaxel/cyclophosphamide (TC) as adjuvant therapy for operable breast cancer.
2006 Cooper, Barry, M.D.
Gregory, T.F.
Baylor University Medical Center Proceedings   Case report of an acquired factor XIII inhibitor: diagnosis and management.
2006 Cooper, Barry, M.D.
Roberts, W.C.
Baylor University Medical Center Proceedings   MD: a conversation with the editor.
2006 Esler, William Vance, M.D.
Rohrer JE, Saeed Q, Saeed S, Periman P, Beggs D, Hancock P, Lim S.H.
Support Care Center   Risk of mistaken DNR orders.
2006 Fay, Joseph Wayne, M.D.
Ueno H, Connolly J, Banchereau J, Palucka AK
Journal of Clinical Oncology   Durable clinical responses in patients with metastatic melanoma vaccinated with dendritic cells loaded with killed allogeneic melanoma cells.
2006 Fay, Joseph Wayne, M.D.
Saracino, G, Agura, E., Berryman, B., Pineiro, L.
American Society of Hematology   Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies Following Sub-myeloablative Conditioning.
2006 Fay, Joseph Wayne, M.D.
Palucka AK, Nemunitis J, Weber J, Ueno H, Auditore-Hargreaves K, Banchereau J
Journal of Clinical Oncology   Vaccination of stage IV melanoma patients with dendritic cells generated ex vivo with type I interferon and loaded with heat-treated killed allogeneic melanoma cells – Preliminary report from the phase II clinical trial.
2006 Hellerstedt, Beth M.D.
Mackler NJ, Dunn RL, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
Cancer   Dose Escalation of Oral Vinorelbine in Combination with Estramustine in Hormone-Refractory Adenocarcinoma of the Prostate
2006 Hoverman, J. Russell M.D.
Syrigos KN, Nutting CM, Roussos C, eds.
Tumors of the Chest - Biology, Diagnosis and Management   Financial Aspects of Lung Cancer.
2006 Hoverman, J. Russell M.D.
Hansen K, Richardson D, Shuey K.M., Dugger P.C.
Journal of Clinical Oncology   The Development of an Outpatient Chemotherapy Medication Safety Program.
2006 Hutson, Thomas E. DO, PharmD, FACP
RM Bukowski
Clinical Genitourinary Cancer   A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
2006 Hutson, Thomas E. DO, PharmD, FACP
Sonpavde G and Berry WR
Cancer Treatment Reviews   Hormone refractory prostate cancer: Management and advances.
2006 Hutson, Thomas E. DO, PharmD, FACP
TK Choueiri, T Mekhail, R Ganapathi, GE Kelly and RM Bukowski
Annals of Oncology   Phase I trial of phenoxodiol delivered by continuous intravenous infusion.
2006 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde, MD Galsky, and WR Berry
Journal of Clinical Oncology   Problems with randomized discontinuation design.
2006 Hutson, Thomas E. DO, PharmD, FACP
G Sonpavde and W Berry
Clinical Genitourinary Cancer   Systemic Chemotherapy for Urothelial Cancer.
2006 Hutson, Thomas E. DO, PharmD, FACP
RJ Halbert, RA Figlin, MB Atkins,  M Bernal, TE Hutson, RG Uzzo, RM Bukowki, KD Khan, RJ Motzer, CG Wood, and  R Dubois
Cancer   Treatment of Patients with Metastatic Renal Cell Carcinoma: A RAND appropriateness panel
2006 Jones, Stephen E. M.D.
Loesch D, Robert N, Elkordy M, Ilegbodu D, Asmar L
Journal of Oncology Practice   A Phase II Trial of a Novel Paclitaxel Schedule as Single-Agent, First-Line Therapy for HER2 neu-Negative Metastatic Breast Cancer
2006 Jones, Stephen E. M.D.

European Journal of Cancer Supplements   Head-to-Head: Docetaxel Challenges Paclitaxel
2006 Jones, Stephen E. M.D.
Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre K, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG and Asmar L
Journal of Clinical Oncology   Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide with Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Operable Breast Cancer
2006 Jones, Stephen E. M.D.
Fallowfield LJ, Bliss JM, Porter LS, Price M H, Snowdon CF, Coombes RC, Hall E
Journal of Clinical Oncology   Qualiity of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane versus Continued Tamoxifen after 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast cancer
2006 Jones, Stephen E. M.D.

Cancer Abstracts and Summaries   The Impact of Aromatase Inhibitors/Inactivators on Quality of Life, Serum Lipid Levels, and Bone Health
2006 Lim, S.H. M.D.
Wang, Z., Zhang, J., Zhang, Y., and Srivenugopal, K.S.
International Journal of Cancer   SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with the MeCP2 protein.
2006 Lim, S.H. M.D.
Wang, Z., Zhang, J., Zhang, Y.
International Journal of Cancer   SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically.
2006 McCollum, David M.D.

Proc (Bayl Univ Med Cent)   Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004.
2006 McCollum, David M.D.
Bingyan Wu, Jeffrey W. Clark, Matthew H. Kulke, Peter C. Enzinger, David P. Ryan, Craig Earle, Ann Michelini, Charles S. Fuchs, MD, MPH.
Americal Journal of Clinical Oncology   The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer.
2006 Patt, Debra M.D.
Giordano, Sharon H.
Women's Health   Paclitaxel in Breast Cancer.
2006 Pippen, John E., JR. MD, F.A.C.P.
Dodwell, D.
Clinical Breast Cancer   Time to response: comparison of fulvestrant and oral endocrine agents.
2006 Shivnani, Anand M.D.
 Rimel BJ, Schink J, and Small W Jr..
Oncology   Cancer of the Cervix: Current Management and New Approaches.
2006 Sonpavde, Guru M.D.

Postgraduate Medicine   Bladder cancer update: current evaluation methods and standard of care.
2006 Sonpavde, Guru M.D.
Hutson TE and Berry WR.
Cancer Treatments Review   Hormone refractory prostate cancer: Management and advances.
2006 Sonpavde, Guru M.D.
Hutson, TE.
American Journal of Clinical Oncology   New approaches in hormone refractory prostate cancer.
2006 Sonpavde, Guru M.D.
Petrylak DP
Critical Reviews of Oncology Hematology   Perioperative chemotherapy for bladder cancer.
2006 Weintahl, Joel M.D.

Oncology Special Edition   Commentary for Huen AO: Tumor lysis syndrome: review of pathophysiology and prevention strategies.